COEP
NASDAQCoeptis Therapeutics Holdings Inc.
$16.27+0.13 (+0.81%)
News25/Ratings0
Price$16.27+0.07 (+0.46%)
01:30 PM07:45 PM
News · 26 weeks35+20%
2025-10-262026-04-19
Mix2690d
- SEC Filings11(42%)
- Insider9(35%)
- Other6(23%)
Latest news
25 items- SECSEC Form 25-NSE filed by Coeptis Therapeutics Holdings Inc.25-NSE - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)
- SECCoeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
- PRZ Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market~ Shares to Commence Trading on the Nasdaq Global Market Under Ticker Symbol "ZSQR" Monday April 27, 2026 ~FORT LAUDERDALE, Fla, April 24, 2026 /PRNewswire/ -- Z Squared, Inc. (NASDAQ:ZSQR) ("Z Squared" or the "Company"), a vertically integrated computing infrastructure company, today announced the completion of its business combination with Coeptis Therapeutics Holdings, Inc. ("Coeptis"). In connection with the business combination, the combined company has been renamed "Z Squared Inc." and its public shares are expected to commence trading on the Nasdaq Global Market under the ticker symbol "ZSQR" on Monday, April 27, 2026 (CUSIP: 98878K108). The closing follows the satisfaction of all con
- SECSEC Form 424B3 filed by Coeptis Therapeutics Holdings Inc.424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
- SECCoeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
- PRCoeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~ WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger Company's common stock on the Nasdaq Global Market under the ticker symbol "ZSQR". The new listing is expected to become effective upon the closing of the proposed merger between the Company and Z Squared, Inc., pursuant to which Z Squared will become a wholly owned subsidiary of Coeptis and th
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Coeptis Therapeutics Holdings Inc.SCHEDULE 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)
- SECSEC Form 424B3 filed by Coeptis Therapeutics Holdings Inc.424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
- SECSEC Form 424B3 filed by Coeptis Therapeutics Holdings Inc.424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
- SECSEC Form 424B3 filed by Coeptis Therapeutics Holdings Inc.424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
- SECSEC Form 10-K filed by Coeptis Therapeutics Holdings Inc.10-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
- INSIDERDirector Deschamps Philippe exercised 5,700 shares at a strike of $10.56 and was granted 3,250 shares, increasing direct ownership by 175% to 8,950 units (SEC Form 4)4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
- INSIDERChief Financial Officer Cogley Brian exercised 10,000 shares at a strike of $10.56 and was granted 12,500 shares, increasing direct ownership by 80% to 22,500 units (SEC Form 4)4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
- INSIDERDirector Cochran Christopher P. exercised 5,700 shares at a strike of $10.56 and was granted 3,250 shares, increasing direct ownership by 175% to 8,950 units (SEC Form 4)4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
- INSIDERDirector Salkind Gene exercised 5,700 shares at a strike of $10.56 and was granted 3,250 shares (SEC Form 4)4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
- INSIDERDirector Calise Chris exercised 5,700 shares at a strike of $10.56 and was granted 3,250 shares (SEC Form 4)4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
- INSIDERVP Operations Yerace Daniel Alexander was granted 20,000 shares and exercised 10,000 shares at a strike of $10.41, increasing direct ownership by 17% to 70,531 units (SEC Form 4)4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
- INSIDERCEO and President Mehalick David exercised 148,875 shares at a strike of $7.05 and was granted 51,250 shares, increasing direct ownership by 82% to 330,192 units (SEC Form 4)4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
- INSIDERVP Compliance and Secy Sheehy Christine Elise exercised 1,000 shares at a strike of $10.56 and was granted 12,500 shares, increasing direct ownership by 2% to 64,031 units (SEC Form 4)4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
- INSIDERDirector Desilva Tara was granted 3,250 shares and exercised 5,700 shares at a strike of $10.56, increasing direct ownership by 175% to 8,950 units (SEC Form 4)4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
- SECCoeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Other Events8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
- PRCoeptis Receives Shareholder Approval Towards Z Squared MergerWEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced that its shareholders have voted to approve the previously announced merger with Z Squared Inc. The transaction was approved on January 30, 2026, by Coeptis' shareholders. In connection with the consummation of the business combination, Z Squared will become a wholly owned subsidiary of Coeptis. The transaction remains subject to satisfaction of the remaining conditions to closing. Additional details regarding the shareholder vote and the proposed merger are included in the Company's Form 8-K f
- SECCoeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
- SECSEC Form SCHEDULE 13G filed by Coeptis Therapeutics Holdings Inc.SCHEDULE 13G - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)
- SECSEC Form 424B3 filed by Coeptis Therapeutics Holdings Inc.424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)